Information Provided By: 
Fly News Breaks for April 4, 2016
EW
Apr 4, 2016 | 07:41 EDT
Jefferies analyst Raj Denhoy says the Sapien 3 data reported over the weekend by Edwards Lifesciences did not disappoint. Showing superiority to surgery on the primary endpoint was the best possible outcome, but the impact will not be that big after a number of very positive recent studies, Denhoy tells investors in a research note. He raised his price target for Edwards shares to $105 from $100 and keeps a Buy rating on the name.
News For EW From the Last 2 Days
There are no results for your query EW
